Essential Innovation and Access

Access to Essential Medicines

The market-driven model of pharmaceutical R&D does not sufficiently respond to the health needs of population groups who represent a commercially-unattractive market; including diseases predominantly found in developing countries. Moreover, even within the EU, recent cuts in medicines expenditure have shown that governments are struggling to pay the price of profit-driven innovation. Sustainability is a real issue and where the market fails, new models of health-driven R&D that promote affordable access must be explored.


HAI applauds Medicines Patent Pool, ViiV Healthcare licensing agreement for new HIV treatment

Read our full statement here.

Status Quo Wins Again

Our statement on the disappointing outcome of WHO Global Technical Meeting is available here.

The Innovative Medicines Initiative 2

A joint policy brief expressing our concerns about the second IMI2 programme can be read here.

Policy Briefs & Reports

May 2013 International briefing note on follow-up of the CEWG report agenda 17.2 at WHA66 (EN)

May 2012 Joint HAI and Allianza LAC-Global Policy Brief - A binding biomedical R&D convention: a structural solution for systemic failure (EN) (ES)

April 2012 Joint HAI Europe - TACD Policy Paper: Time for the EU to lead on innovation: EU policy opportunities in biomedical innovation and the creation of public knowledge goods (EN)